Lupus & antiphospholipid syndrome
Development and validation of the SLE Disease Activity Questionnaire (SLEDAQ)
Authors' conclusion
SLEDAQ is a novel patient-reported measure that more closely aligns with physician-assessed disease activity than previously available instruments. Findings support its potential usefulness in observational research and clinical settings where in-person disease activity assessment is limited.
Study context
- Population
- Patients with SLE at two clinical sites
- Index test or model
- Correspondence of SLEDAQ items with the SLE Disease Activity Index (SLEDAI) domain scores
- Target condition
- SLE Disease Activity Index (SLEDAI) domain scores
Methodological detailsSLEDAQ, patient-reported measure, items pre-tested in individual interviews, administered at two clinical sites
- SLEDAQ
- Patient-reported measure
- Items pre-tested in individual interviews
- Administered at two clinical sites
Performance
As reported in the abstract
Agreement between SLEDAQ and SLEDAI scoring, all domains
≥63%
All specificity estimates
≥0.63
Further findings
Correlations between SLEDAQ and SLEDAI, clinical SLEDAI and physician global assessments (PGA) scores
- SLEDAI
- 0.25
- Clinical SLEDAI
- 0.37
- PGA
- 0.34
SLEDAQ scores by SLEDAI severity groupings
- SLEDAQ scores differentiated between SLEDAI severity groupings
Performance compared with Systemic Lupus Activity Questionnaire (SLAQ)
- Performance on all metrics exceeded that of the SLAQ
SLEDAQ by sex, education, health literacy and fibromyalgia
- No differences in SLEDAQ by sex or education
- SLEDAQ scores significantly higher among individuals with low health literacy and fibromyalgia; differences by health literacy attenuated after adjustment for SLEDAI
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →